Contracts & Pricing March 28, 2022 Medicare Part B Sequestration Update 3 Minute Read Regulatory Market Update Updates for Pharma Manufacturers As always, if you have questions on any of the content found in this or previous market updates, please reach out to...
Contracts & Pricing February 24, 2022 Branded Pharma Fee: Manufacturer Considerations 5 Minute Read And other regulatory updates on Line Extension guidance, the upcoming DUNS number transition, and emergency 340B flexibilities.
Contracts & Pricing January 24, 2022 New Year, New Laws: Drug Price Reform, Coverage Gap, and 340B 4 Minute Read Potential and pending regulatory changes in 2022 including the current status of the Build Back Better Act and Part D Benefit Design.
Channel December 20, 2021 Retail Pharmacy’s Digital Transformation 3 Minute Read As society shifts toward digital and delivery-based economies, we ask: what will pharmacies look like in the future?
Contracts & Pricing November 23, 2021 Regulatory Updates 4 Minute Read This month we discuss COVID-19 vaccine mandates, the recent HHS drug discount ruling, and Medicare drug price reforms.
Contracts & Pricing October 20, 2021 The New Plan for Addressing High Drug Prices 4 Minute Read We discuss the Biden administration's plan for combatting high drug prices, the new PBM public law reporting cycle, and MA and Part D rule for 2022.
Contracts & Pricing September 17, 2021 How Discount Cards Are Replacing PBMs 3 Minute Read We review how discount cards have disrupted the prescription market as well as updates to the most-favored-nation pricing model and new STPR laws in Maine.
Contracts & Pricing August 13, 2021 Compliance Guidelines for Government Programs 5 Minute Read Six key elements to operate an effective compliance program. Also, new VA FSS rules for vaccine drugs, State Price Transparency, and Medicare Part D updates and reminders.
Contracts & Pricing July 26, 2021 The Branded Pharma Fee Deadline Approaches 4 Minute Read We'll tell you how to prepare. Plus new manufacturer awareness for orphan drugs, midnight changes to MDRP, and upholding the ACA.
